Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.

ABSTRACT:

Background

Patients with head and neck squamous cell carcinoma (HNSCC), particularly the human papillomavirus negative (HPV^-) subset, have a dismal prognosis. Furthermore, patients with Fanconi anemia (FA) have a genetic predisposition with a 500-fold to 700-fold higher incidence of HNSCC. Thus, novel and more efficacious therapies are needed. As current immunotherapies often fail due to suppressive elements in the tumor microenvironment (TME), we developed a trispecific killer engager (TriKE) to direct multiple signals to natural killer (NK) cells to overcome the hypoxic TME. This TriKE is comprised of a camelid nanobody that binds to CD16 on NK cells, an interleukin (IL)-15 moiety, and another novel camelid nanobody that binds to the B7-H3 antigen, which is highly and

SUBMITTER: Khaw MJ 

PROVIDER: S-EPMC12306285 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature